Our findings support early monitoring of adalimumab serum levels to guide dose optimisation, which may prevent immunogenicity and influence long-term outcome. We validated a novel lateral flow assay for quantitative determination of adalimumab levels, facilitating physicians to optimise therapy immediately at the outpatient clinic.

Hepatocellular adenoma (HCA) is an uncommon benign liver neoplasm usually solitary and identified incidentally on imaging. We report a case of a 50-year old female who was diagnosed with multiple hepatic adenomas of the inflammatory subtype. After discontinuation of oral contraception a decrease of both the number and size of the liver lesions was seen on magnetic resonance imaging (MRI) without the need of further intervention. The major challenge in the clinical management of patients with multiple HCAs resides in the risk assessment for future complications. In the case of multiple HCAs subtype seemed to be more relevant than the actual number of lesions. Because little is known about the natural evolution in patients with multiple HCAs, we performed a review of the current literature with focus on the different subtypes and their clinical relevance.

Abstracts of the 13 th Congress of ECCO -European Crohn's and Colitis Organisation S373severe disease on US with BWT ≥7mm and/or sonographic complications (strictures/penetrating complications). Background: Adalimumab (ADM) serum levels (SL) during maintenance are associated with treatment outcome and need for doseescalation in Crohn's disease (CD) patients. Little is known about the clinical relevance of proactive testing of ADM SL during induction. We evaluated correlation between ADM SL at Week 4, ADM anti-drug antibody (ADA) presence and outcome. Methods: Serum samples from biologically naïve CD patients were prospectively collected at trough at Weeks 4 and 12 after ADM initiation. Clinical remission was defined as an average daily stool frequency ≤2.8 and an average abdominal pain score ≤1. In patients with an elevated baseline C-reactive protein (CRP), biochemical remission was defined as a CRP ≤5.0 mg/l and response as a decrease of at least 50% or CRP normalisation. ADM SL were measured with a novel ADM RIDA Conclusions

No abstract

No abstract